首頁 > 市場調查報告書 > 製藥

醫藥品法規環境

市場調查報告書

商品編碼

1547860

全球藥物警戒市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

Global Pharmacovigilance Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 170 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球藥物警戒市場需求預計將從 2023 年的 88.3 億美元達到近 193 億美元的市場規模，2024-2032 年研究期間複合年成長率為 9.08%。

藥物警戒是一門與檢測、收集、評估、了解、監測和預防藥物不良反應或任何其他藥物相關問題相關的科學。藥品不良反應（ADR）是藥品在臨床使用過程中發生的不良或有害反應。不良反應可能有多種類型，包括藥物毒性。藥物警戒涉及了解和識別藥品的有害影響，並有助於降低患者的風險。藥物警戒是藥物發現和開發過程中不可避免的一部分。隨著藥物消費量的不斷成長，對適當藥物警戒的需求也不斷增加。

市場動態

推動全球藥物警戒市場的主要力量包括不斷成長的藥物消費、快速推進的藥物發現和開發以及不斷上升的藥物不良反應和藥物毒性發生率。此外，對個人化醫療的日益偏好和外包藥物警戒服務趨勢的上升等因素預計將培育全球市場。資訊系統和 ADR 資料庫的進步也支持藥物警戒市場的成長。由於全球製藥商正在努力開發針對該疾病的藥物，預計在預測期內，COVID-19 大流行將更有力地刺激市場。然而，供應鏈中斷可能會在一段時間內擾亂全球市場。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球藥物警戒市場的每個細分市場進行包容性評估。藥物警戒產業的成長和趨勢為本研究提供了整體方法。

市場區隔

藥物警戒市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按藥物開發

臨床前研究
第一階段
第二階段
第三階段
第四階段或上市後監督

依方法類型

自發性報告
強化 ADR 報告
針對性的自發性報告
群組事件監控
電子病歷採礦

按服務類型

內部
合約外包

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲藥物警戒市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。藥物警戒市場的主要參與者包括埃森哲公司、百時美施貴寶公司、Clinquest Group BV、Cognizant、Labcorp Drug Development、F. Hoffmann-La Roche Ltd.、葛蘭素史克公司、ICON Plc、IGATE Corporation、IMEDGlobal Corporation 、Syneos Health、諾華公司、Parexel International Corporation、輝瑞公司、藥品開發有限責任公司。 (PPD)、IQVIA、賽諾菲。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：藥物警戒公司的競爭格局

藥物警戒市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

頂級公司市佔率分析
市場集中度
Accenture Plc

公司概況
公司收入
產品
最新動態

Bristol-Myers Squibb

公司概況
公司收入
產品
最新動態

Clinquest Group BV

公司概況
公司收入
產品
最新動態

Cognizant

公司概況
公司收入
產品
最新動態

Labcorp Drug Development

公司概況
公司收入
產品
最新動態

F. Hoffmann-La Roche Ltd.

公司概況
公司收入
產品
最新動態

GlaxoSmithKline Plc

公司概況
公司收入
產品
最新動態

ICON Plc

公司概況
公司收入
產品
最新動態

IGATE Corporation

公司概況
公司收入
產品
最新動態

IMEDGlobal Corporation

公司概況
公司收入
產品
最新動態

Syneos Health

公司概況
公司收入
產品
最新動態

Novartis AG

公司概況
公司收入
產品
最新動態

Parexel International Corporation

公司概況
公司收入
產品
最新動態

Pfizer Inc.

公司概況
公司收入
產品
最新動態

Pharmaceutical Product Development LLC. (PPD)

公司概況
公司收入
產品
最新動態

IQVIA

公司概況
公司收入
產品
最新動態

Sanofi

公司概況
公司收入
產品
最新動態

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR11212767

The global demand for Pharmacovigilance Market is presumed to reach the market size of nearly USD 19.3 Billion by 2032 from USD 8.83 Billion in 2023 with a CAGR of 9.08% under the study period 2024-2032.

Pharmacovigilance is a science related to the detection, collection, assessment, understanding, monitoring, and prevention of adverse effects or any other drug-related problem with the pharmaceutical products. An adverse drug reaction (ADR) is an adverse or harmful reaction of medicines that occurred during its clinical use. The adverse reaction may be of various types including drug toxicity. Pharmacovigilance deals with understanding and identifying the harmful effects of pharmaceutical products and aids in reducing the risk to the patients. Pharmacovigilance is an unavoidable part of drug discovery and development procedures. With the growing consumption of medicines, the need for the proper pharmacovigilance is also accelerated.

MARKET DYNAMICS

The prime forces that are driving the global pharmacovigilance market include growing drug consumption, rapidly advancing drug discovery and development, and rising incidences of adverse drug reactions & drug toxicity. Furthermore, factors such as a growing preference for personalized medicine and a rising trend for outsourcing pharmacovigilance services are expected to foster the global market. The advancement in information systems and ADR databases is also supporting the growth of the pharmacovigilance market. COVID-19 pandemic is anticipated to stimulate the market more energetically, during the forecast period, as the global pharmaceutical manufacturers are working strenuously to discover the drug against the disease. However, supply chain disruption may agitate the global market for some period.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Pharmacovigilance. The growth and trends of Pharmacovigilance industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Pharmacovigilance market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Development

Preclinical Studies
Phase I
Phase II
Phase III
Phase IV or Post Marketing Surveillance

By Type of Methods

Spontaneous Reporting
Intensified ADR Reporting
Targeted Spontaneous Reporting
Cohort Event Monitoring
EHR Mining

By Type of Service

In-house
Contract Outsourcing

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Pharmacovigilance market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Pharmacovigilance market include Accenture Plc, Bristol-Myers Squibb, Clinquest Group B.V., Cognizant, Labcorp Drug Development, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, ICON Plc, IGATE Corporation, IMEDGlobal Corporation, Syneos Health, Novartis AG, Parexel International Corporation, Pfizer Inc., Pharmaceutical Product Development LLC. (PPD), IQVIA, Sanofi,. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. PHARMACOVIGILANCE - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Development
- 3.7.2 Market Attractiveness Analysis By Type of Methods
- 3.7.3 Market Attractiveness Analysis By Type of Service
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL PHARMACOVIGILANCE MARKET ANALYSIS BY DRUG DEVELOPMENT

5.1. Overview By Drug Development
5.2. Historical and Forecast Data
5.3. Analysis By Drug Development
5.4. Preclinical Studies Historic and Forecast Sales By Regions
5.5. Phase I Historic and Forecast Sales By Regions
5.6. Phase II Historic and Forecast Sales By Regions
5.7. Phase III Historic and Forecast Sales By Regions
5.8. Phase IV or Post Marketing Surveillance Historic and Forecast Sales By Regions

6. GLOBAL PHARMACOVIGILANCE MARKET ANALYSIS BY TYPE OF METHODS

6.1. Overview By Type of Methods
6.2. Historical and Forecast Data
6.3. Analysis By Type of Methods
6.4. Spontaneous Reporting Historic and Forecast Sales By Regions
6.5. Intensified ADR Reporting Historic and Forecast Sales By Regions
6.6. Targeted Spontaneous Reporting Historic and Forecast Sales By Regions
6.7. Cohort Event Monitoring Historic and Forecast Sales By Regions
6.8. EHR Mining Historic and Forecast Sales By Regions

7. GLOBAL PHARMACOVIGILANCE MARKET ANALYSIS BY TYPE OF SERVICE

7.1. Overview By Type of Service
7.2. Historical and Forecast Data
7.3. Analysis By Type of Service
7.4. In-house Historic and Forecast Sales By Regions
7.5. Contract Outsourcing Historic and Forecast Sales By Regions

8. GLOBAL PHARMACOVIGILANCE MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE PHARMACOVIGILANCE COMPANIES

9.1. Pharmacovigilance Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF PHARMACOVIGILANCE INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Accenture Plc
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Bristol-Myers Squibb
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Clinquest Group B.V.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Cognizant
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Labcorp Drug Development
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. F. Hoffmann-La Roche Ltd.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. GlaxoSmithKline Plc
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. ICON Plc
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. IGATE Corporation
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. IMEDGlobal Corporation
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Syneos Health
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. Novartis AG
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments
10.15. Parexel International Corporation
- 10.15.1 Company Overview
- 10.15.2 Company Revenue
- 10.15.3 Products
- 10.15.4 Recent Developments
10.16. Pfizer Inc.
- 10.16.1 Company Overview
- 10.16.2 Company Revenue
- 10.16.3 Products
- 10.16.4 Recent Developments
10.17. Pharmaceutical Product Development LLC. (PPD)
- 10.17.1 Company Overview
- 10.17.2 Company Revenue
- 10.17.3 Products
- 10.17.4 Recent Developments
10.18. IQVIA
- 10.18.1 Company Overview
- 10.18.2 Company Revenue
- 10.18.3 Products
- 10.18.4 Recent Developments
10.19. Sanofi
- 10.19.1 Company Overview
- 10.19.2 Company Revenue
- 10.19.3 Products
- 10.19.4 Recent Developments